Please use this identifier to cite or link to this item: https://hdl.handle.net/10419/268413 
Authors: 
Year of Publication: 
2023
Publisher: 
University of California Press, Oakland
Abstract: 
Capitalizing a Cure takes readers into the struggle over a medical breakthrough to investigate the power of finance over business, biomedicine, and public health. When curative treatments for hepatitis C launched in 2013, sticker shock over their prices intensified the global debate over access to new medicines. Weaving historical research with insights from political economy and science and technology studies, Victor Roy demystifies an oft-missed dynamic in this debate: the reach of financialized capitalism into how medicines are made, priced, and valued. Roy’s account moves between public and private labs, Wall Street and corporate board rooms, and public health meetings and health centers to trace the ways in which curative medicines became financial assets dominated by strategies of speculation and extraction at the expense of access and care. Provocative and sobering, this book illuminates the harmful impact of allowing financial markets to determine who heals and who suffers and points to the necessary work of building more equitable futures.
Subjects: 
capitalization
capital as power
finance
Gilead Sciences
health
pharmaceutical
price
profit
R&D
sabotage
Thorstein Veblen
JEL: 
P16
I1
G
ISBN: 
978-0-520-38872-7
Creative Commons License: 
cc-by-nc-nd Logo
Document Type: 
Book
Document Version: 
Published Version

Files in This Item:
File
Size





Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.